Cargando…

Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy

BACKGROUND: Statins may reduce the risk of first and recurrent venous thromboembolism (VTE). No data are available on their potential benefit in patients treated with the oral anticoagulant rivaroxaban. METHODS: The EINSTEIN DVT/PE and EINSTEIN Extension studies compared rivaroxaban with standard of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wells, Philip S, Gebel, Martin, Prins, Martin H, Davidson, Bruce L, Lensing, Anthonie WA
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Original Clinical Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334416/ https://www.ncbi.nlm.nih.gov/pubmed/25698905 http://dx.doi.org/10.1186/1477-9560-12-26

Ejemplares similares

Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism
por: Bistervels, Ingrid M., et al.
Publicado: (2022)

Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban‐treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding
por: Kline, Jeffrey A., et al.
Publicado: (2016)

Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism
por: Prins, Martin H, et al.
Publicado: (2013)

Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin
por: Boonyawat, Kochawan, et al.
Publicado: (2021)

Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies
por: Prins, Martin H, et al.
Publicado: (2013)

Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment
por: Bauersachs, Rupert M, et al.
Publicado: (2014)

Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study
por: Lensing, Anthonie W. A., et al.
Publicado: (2018)

Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program
por: Yamada, Norikazu, et al.
Publicado: (2015)

Erratum to: ‘Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program’
por: Yamada, Norikazu, et al.
Publicado: (2016)

Anticoagulation in pediatric cancer–associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr
por: Palumbo, Joseph S., et al.
Publicado: (2022)

Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism
por: Berger, Jeffrey S., et al.
Publicado: (2017)

Use of Prestudy Heparin Did Not Influence the Efficacy and Safety of Rivaroxaban in Patients Treated for Symptomatic Venous Thromboem‐bolism in the EINSTEIN DVT and EINSTEIN PE Studies
por: Prandoni, Paolo, et al.
Publicado: (2015)

Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis
por: Khan, Faizan, et al.
Publicado: (2019)

Direct oral anticoagulants in pediatric venous thromboembolism: Review of approved products rivaroxaban and dabigatran
por: Al-Ghafry, Maha, et al.
Publicado: (2022)

Rivaroxaban for cancer-associated venous thromboembolism
por: Liang, Bo, et al.
Publicado: (2021)

Recurrent thromboembolism, bleeding, and mortality in Asian patients with venous thromboembolism receiving different oral anticoagulants: A nationwide analysis
por: Lee, Mei-Chuan, et al.
Publicado: (2022)

Platelet Count and Bleeding in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism: Lesson from the RIETE Registry
por: Di Micco, Pierpaolo, et al.
Publicado: (2019)

Treatment of Pulmonary Embolism With Rivaroxaban: Outcomes by Simplified Pulmonary Embolism Severity Index Score from a Post Hoc Analysis of the EINSTEIN PE Study
por: Fermann, Gregory J, et al.
Publicado: (2015)

Validation of venous thromboembolism diagnoses in patients receiving rivaroxaban or warfarin in The Health Improvement Network
por: Ruigómez, Ana, et al.
Publicado: (2020)

Fatigue after initiating rivaroxaban for venous thromboembolism
por: Karlsvik, Tina Margrethe, et al.
Publicado: (2020)

Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding
por: Caroti, Kimberly Snow, et al.
Publicado: (2023)

Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score
por: de Winter, Maria A, et al.
Publicado: (2023)

Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE
por: Ageno, Walter, et al.
Publicado: (2017)

Claims‐Based Score for the Prediction of Bleeding in a Contemporary Cohort of Patients Receiving Oral Anticoagulation for Venous Thromboembolism
por: Alonso, Alvaro, et al.
Publicado: (2021)

Sex Differences in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism
por: Blanco-Molina, Angeles, et al.
Publicado: (2014)

Oral Rivaroxaban Versus Standard Therapy in Acute Venous Thromboembolism Treatment for Vietnamese Patients
por: Bui, My Hanh, et al.
Publicado: (2019)

Direct Oral Anticoagulants or Standard Anticoagulant Therapy in Fragile Patients with Venous Thromboembolism
por: López-Núñez, Juan J., et al.
Publicado: (2019)

Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis
por: Lipardi, Concetta, et al.
Publicado: (2021)

Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism
por: Wells, Philip S., et al.
Publicado: (2022)

Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
por: Bauersachs, Rupert, et al.
Publicado: (2020)

Rivaroxaban in acute venous thromboembolism: UK prescribing experience
por: Speed, Victoria, et al.
Publicado: (2021)

Risk of intracranial bleeding in patients with primary brain cancer receiving therapeutic anticoagulation for venous thromboembolism: A meta‐analysis
por: Porfidia, Angelo, et al.
Publicado: (2020)

Prediction of Major Bleeding in Anticoagulated Patients for Venous Thromboembolism: Comparison of the RIETE and the VTE-BLEED Scores
por: Lecumberri, Ramón, et al.
Publicado: (2021)

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban
por: Kirchhof, Paulus, et al.
Publicado: (2020)

Fatal Events in Cancer Patients Receiving Anticoagulant Therapy for Venous Thromboembolism
por: Farge, Dominique, et al.
Publicado: (2015)

Venous Thromboembolism in Hospitalized Patients With COVID-19 Receiving Prophylactic Anticoagulation
por: Boonyasai, Romsai T., et al.
Publicado: (2020)

Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants
por: Wallvik, Niklas, et al.
Publicado: (2020)

Assessment of bleeding risk in cancer patients treated with anticoagulants for venous thromboembolic events
por: Poénou, Géraldine, et al.
Publicado: (2023)

Risk of recurrence and bleeding in patients with cancer‐associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study
por: Søgaard, Mette, et al.
Publicado: (2019)

Delayed Thrombin Generation Is Associated with Minor Bleedings in Venous Thromboembolism Patients on Rivaroxaban: Usefulness of Calibrated Automated Thrombography
por: Zalewski, Jaroslaw, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7ifi2103svmpalc5pno2nvqhro